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Abstract 
Fifty per cent of first-degree relatives of index cases with familial 
hypercholesterolemia (FH) inherit the disorder. Despite cascade screening being the 
most cost-effective method for detecting new cases, only a minority of individuals 
with FH are currently identified. Primary care is a key target area to increase 
identification of new index cases and initiate cascade screening, thereby finding 
close relatives of all probands. Increasing public and health professional awareness 
about FH is essential. 
In the United Kingdom and in Australia, most of the population are reviewed by a 
General Practitioner (GP) at least once over a three-year period, offering 
opportunities to check for FH as part of routine clinical consultations. Such 
opportunistic approaches can be supplemented by systematically searching 
electronic health records with information technology tools that identify high risk 
patients.  GPs can help investigate and implement results of this data retrieval. 
Current evidence suggests that early detection of FH and cascade testing meet most 
of the criteria for a worthwhile screening program. Among heterozygous patients the 
long latent period before the expected onset of coronary artery disease provides an 
opportunity for initiating effective drug and lifestyle changes. The greatest challenge 
for primary care is to implement an efficacious model of care that incorporates 
sustainable identification and management pathways. 
Word count: 209 
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Introduction 
There is a general lack of public1-3 and health professional4-7 awareness of 
heterozygous Familial hypercholesterolaemia (FH) as a common, autosomal 
dominant disorder of lipid metabolism8-10. FH can cause premature coronary artery 
disease (CAD) if left untreated11 with up to 50% of males likely to develop CAD by 
age 50 years and 30% of females similarly affected by age 60 years. Owing to a 
genetic defect in the low-density lipoprotein (LDL)-receptor pathway, affected 
patients cannot clear LDL particles from the circulation, which untreated leads to life-
long, accumulation of low-density lipoprotein cholesterol (LDL-c) in plasma and 
accelerated atherosclerosis8, 10, 12, 13. FH patients cannot be managed solely by diet 
and lifestyle modifications. The cumulative cholesterol burden in homozygous FH is 
much greater as the condition is inherited from both parents8. Such patients develop 
severe life-threatening coronary heart disease (CHD) and other vascular 
complications in late childhood and adolescence if not recognised and treated. 
FH affects 1 in 250 of the population14-16. Such a prevalence would expect to yield 
over 30 million patients worldwide, 240,000 in the United Kingdom (UK) and 90,000 
in Australia. With over 85% of the Australian and UK population attending a General 
Practitioner (GP) at least once a year17-19, opportunities exist for primary care to play 
a much more active role in the detection and care of FH patients in the future.  
Despite increasing knowledge of the clinical hallmarks of FH – elevated LDL-c levels, 
family and personal history of premature coronary heart disease, premature arcus 
cornealis and tendon xanthomata, most cases of FH are still not being recognised1, 9, 
12. Amongst patients recognised as having FH, most remain under-treated9. Various 
explanations have been offered to explain these missed opportunities for diagnoses 
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including busy clinical settings at tertiary and primary care level, pressure on bed 
availability and early discharge policies from hospitals.20 Increasing complexity and 
amount of multimorbidity21 in routine clinical presentations to GPs make recognition 
of FH especially challenging22. 
Coronary care units are other settings where FH may be identified. Patients with 
early onset of symptoms of ischemic heart disease may be admitted for further 
assessment and treatment. Such encounters will usually involve a shared care role 
for GPs, cardiologist and hospital specialist. Evidence to date suggests these are 
often missed opportunities for FH diagnoses in some patients20. 
Effective treatment is available and earlier beliefs that regression of atheromatous 
plaques could not be achieved are being challenged with studies showing intensive 
drug therapy can have a beneficial effect23, 24. Compliance with optimum treatment, 
usually statins, can be problematic at both patient and health professional levels12, 25 
and needs regular review and re-enforcement. 
We review the potential to increase the role of primary care in the detection and care 
of FH.  
International guidelines and approaches 
The Consensus Statement of the European Atherosclerosis Society9 and the 
International FH Foundation26 both recommend that most patients with FH should be 
managed in the primary care setting and preferably in the family context. They 
advise that there should be provision for more complex cases, including children, to 
be managed through specialist lipid or FH clinics. 
It is increasingly recognised that childhood and early adolescence offer the most 
favourable timeframe for diagnosing FH as well as introducing and maintaining 
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lifelong treatment and management strategies3, 9, 12. To achieve such radical care 
from a young age will require a shift in community and health professional 
perceptions of FH and its effects on the young. Little attention has been given to date 
to screening for FH in general practice where most affected patients are found. 
In countries with a history of dedicated screening programs, such as the Netherlands 
and Norway, the outcomes in terms of newly diagnosed FH index cases and 
cascade tested relatives are much higher than countries lacking any formal 
screening program (usually <1%)9, 27. 
Evidence suggests that cascade screening of close relatives is generally highly 
acceptable and does not impact on quality of life27. The Dutch FH cascade screening 
program operated between 1994 and 2014 using the services of genetic field 
workers and was very successful27. Since the program was modified due to changes 
in the Dutch Health System, numbers diagnosed have dropped27. 
Most Australian and UK primary care practices are fully computerised, often with 
links to pathology providers and hospital services, thus lending themselves to 
electronic examination of patient databases for chronic hereditary conditions such as 
FH.  In Australia, laboratory alerts either through a direct telephone call28 from the 
chemical pathologist to GP or through flagging of raised lipids reports raising 
possibility of FH29, 30 have been successful. Other Australian community-based 
initiatives include examining general practice and laboratory databases31, use of 
algorithm32 or data extractions tools33. 
In the UK, the accessibility to most GPs of regionally located specialist lipid clinics 
has provided valuable additional support for primary care management34 while GP-
based approaches involving database searches have also been trialled35, 36. 
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In Slovenia, the use of universal screening for children aged over 5 years has been 
introduced to help with the detection of FH37, but the practicalities and cost-
effectiveness remain to be confirmed. In the United States, universal screening of 
cholesterol at age 9 to 11 has been endorsed by the American Academy of 
Pediatrics and the National Lipid Association (NLA), but has been incompletely 
undertaken and cost benefit analyses of this approach have not been performed65.  
Screening for FH in primary care 
Primary care based screening for FH fulfils many of the revised Wilson and Jungner 
criteria38, including the updated Australian Government population screening 
guidelines39 (See Table 1) 
Advances in approaches to screening in primary care 
Primary care can make a more substantial contribution to the detection and care of 
FH33, 36, 40. Tests to help diagnose FH are simple and acceptable to the public, the 
available treatment is effective and case finding can take place in clinical practice12. 
The latent period between potential diagnosis of FH (preferably in childhood or 
adolescence) and the onset of CHD (early middle age) is in theory sufficient to allow 
effective, lifelong treatment to be instituted before atheromatous plaque development 
occurs. This time-frame is critical to facilitate an improved primary care role in FH 
recognition12. 
 Research on strategies to identify FH in primary care: 
1. Child-parent screening / Reverse cascade screening 
Wald et al.40 examined the efficacy and feasibility of child-parent screening for FH in 
primary care practices. They undertook the screening at routine immunisation 
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attendances by children aged 1 – 2 years at 92 general medical practices in the 
United Kingdom over a three-year period. A total of 84% of parents agreed to the 
heel-stick capillary blood sampling offered to test for FH. The child provided the 
screening entry point at an age identified as the most discriminatory for the 
measurement of cholesterol41. Once the child is identified as having FH, one of the 
parents will also harbour the condition enabling two generations to be effectively 
screened as part of the process.  
For the 10,000 children screened, based on cholesterol levels, 40 children and 40 
parents were identified as positive for FH, at high risk for cardiovascular disease 
(CVD) and offered appropriate treatments40. The population prevalence of children 
found to have FH was 1 in 270. A total of 32 of the 40 children screening positive for 
FH were found to have a genetic mutation while 8 did not. Child-parent screening 
was seen as a simple, effective and practical method to examine a population for the 
presence of FH40. 
2. Systematic and opportunistic screening and case finding in general 
practice 
Primary care can significantly improve the identification and management of FH in 
the general population3, 9, 12, 31 where the prevalence is about twice that previously 
estimated14-16, 26. A prevalence of 1 in 250 would yield 40 individuals with FH in a 
practice population of 10,000 patients. Most practices of this size would not realise 
this potential at risk group exists. For primary care to improve FH detection, greater 
health professional awareness of the significance of markedly elevated cholesterol 
levels in high risk patients, a family or personal history of premature CAD or death 
plus recognition of other tell-tale stigmata of FH, will be necessary1, 3. 
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Extra workloads 
Opportunities to increase detection of FH in general practice are becoming more 
sophisticated. New data extraction tools employing algorithms of the phenotypic 
features of FH (Dutch Lipid Clinic Network (DLCN)42, Make Early Diagnosis to 
Prevent Early Deaths (MEDPED)43 and Simon-Broome (S-B) criteria44) can minimise 
practice workloads while still focussing attention on detecting high risk patients. 
In Australia, there have been attempts at improving detection and management of 
FH in the primary care sector33, 45-47. Models of care, which in the past have focussed 
on tertiary level hospital lipid clinics3, are now looking at a greater involvement from 
primary care especially for patients without additional risk factors22, 41. 
Phenotypic v genetic testing 
The DLCN criteria (DLCNC) score42 is the preferred tool in Australia to help with 
phenotypic diagnosis of FH26. Cost, geographic and migration factors, plus lack of 
population density across most of the continent, are major handicaps towards use of 
genetic testing for all suspected FH patients22. The same barriers also preclude the 
widespread use of dedicated field workers27 to undertake systematic contact tracing 
of close relatives. A more pragmatic approach involving use of the DLCNC score in 
the primary care setting is currently being trialled in Australia47. 
The use of genetic testing in the UK compared with the phenotypic approach 
advocated in Australia and in the United States offers an interesting comparison34. 
Current National Institute for Health and Care Excellence (NICE) guidelines17 favour 
the critical importance of genetic testing to confirm monogenic FH. Only patients 
testing positive to the FH gene mutation will be given the diagnosis of FH. Other 
patients with the clinical features of FH (phenotypic) but no established mutation will 
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be designated as ‘polygenic hypercholesterolemia’. NICE guidelines17 also advocate 
that only relatives of genetically positive index cases should be offered genetic 
testing to establish mutation positive FH. The obvious downside is that with over 
1700 known FH mutations48, not all are amenable to genetic testing and up to 40% 
may be missed9. 
National Institute for Health and Care Excellence (NICE) guidelines 
In UK, the original NICE Guideline CG7117 advised suspicion of FH diagnosis in 
adult if raised total cholesterol (> 7.5 mmol/l) especially with personal or family 
history of premature CHD. GPs should exclude secondary causes of FH, undertake 
detailed family history that is regularly updated and undertake thorough clinical 
examination to check for signs of elevated cholesterol, such as, tendon 
xanthomata34. Patients with ’definite’ or ‘possible’ FH on S-B criteria should be 
referred to specialist with FH expertise to confirm diagnosis, advise on management 
and help with co-ordination of cascade testing among close relatives. Many patients 
identified as ‘possible’ FH will not be confirmed as having the condition49. The 2017 
NICE guidelines advise systematic searches of patient records for cholesterol over 
9mmol/l as these have over 25% chance of having FH17. 
The absence of suitable infrastructure in primary care to assist with cascade testing 
of relatives is a major handicap2. Serious deficiencies have been found in patient 
knowledge about FH, their risk of a major cardiac event and the mode of inheritance 
across generations50. 
General practice search strategies 
Gray et al.35 undertook computer-based searches to look for likely FH patients at a 
primary care centre of 12,000 patients in South London. A total of 402 individual 
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patients were identified for review.  After record review and using the DLCNC 
score42, they identified 12 patients who scored 8 and above (’definite’ FH); eight who 
score between 6 and 8 (‘probable’ FH) and a further 47 patients who scored between 
3 and 5 (‘possible’ FH).  Thus, a total of 20 patients met the criteria for ‘definite’ or 
‘probable’ FH in the study. No cases with tendon xanthomata were found.  
All patients with FH were noted to have early CAD and the authors concluded this 
finding as the key to reaching a diagnosis of FH. Commencement of treatment for 
elevated lipids with statins was noted to occur without the potential for FH being the 
key diagnosis being considered. This lost opportunity to screen close family 
members for the condition could have contributed to avoidable mortality in the 
circumstances35. 
The time factor involved was a limiting factor. Each manual search of medical 
records took about 30 minutes and amounted to 201 hours of additional work to 
examine the records of the 402 patients identified as being at higher risk35. The use 
of electronic screening tools combined with efficient clinical follow-up by GP and/or 
PN can offer a more time- and cost-effective systematic approach to identify FH 
patients in the primary care setting. 
Familial Hypercholesterolaemia Case Ascertainment Tool (FAMCAT) 
To improve and simplify identification of FH in British primary care electronic health 
records, a case ascertainment tool - Familial Hypercholesterolaemia Case 
Ascertainment Tool  (FAMCAT)36 was developed to identify those with the highest 
probability of the condition, with predictive accuracy (AUC) of 86%. FAMCAT allows 
more efficient use of limited resources by identifying those that need further clinical 
assessment, undergo referral for diagnosis and commencement of appropriate 
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preventative care for the future. Because patient health data is generally well 
recorded in the electronic medical records in general practices, FAMCAT uses coded 
variables to enhance the discriminatory information to identify the highest risk 
patients for further evaluation. This has been integrated into a national quality 
improvement tool51. 
TARB-Ex 
In Australia, TARB-Ex33 is an electronic research screening tool that uses 
information from regular general practice databases to identify patients with high 
DLCN scores who are then invited to attend the practice for further clinical 
investigation and phenotypic diagnosis. It was developed using Structured Query 
language (SQL) technology and integrated into Best Practice clinical software52. It 
has the capacity to be adapted for other SQL-based practice software including 
Medical Director, ZedMed, MedTech, Practix and Monet which taken together 
account over 90% of clinical software in Australia.  
The performance of TARB-Ex was evaluated against a manual assessment by a GP 
of a subset of patients attending the practice33. Overall, results suggested that 
TARB-Ex was a fast and effective method for systematically identifying patients 
attending the practice with potential high risk of FH to enable further clinical 
investigation. Additional costs to the practice in terms of manpower and GP workload 
were minimised. TARB-Ex showed high sensitivity, specificity and negative 
predictive power, comparing favourably with manual review in just a fraction of the 
time – 10 minutes v 60 hours for manual review33. 
TARB-Ex integrates well into regular clinical practice. A GP, Practice Nurse (PN) or 
Practice Manager can undertake the initial screening process prior to recall for 
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clinical review. GP and PN involvement is limited to reviewing medical records of 
patients identified by TARB-Ex with high DLCNC scores and at risk for FH, exclude 
confounding secondary causes and decide which patients merit recall for clinical 
review. 
Limitations of screening tools 
All electronic screening tools are only as effective as the quality of the medical and 
blood pathology information stored in practice databases. The experience in UK and 
Australia shows family histories are poorly recorded for many patients53-57 and is an 
acknowledged limitation of GP-based databases in comparison with hospital-based 
admissions and discharge summaries. 
3. Community pathology alerts to GPs 
Attempts have been made to link the performance of community pathology 
laboratories and general practice databases29, 31 to help identify patients with specific 
indicators suggestive of FH and facilitate clinical follow-up. Evidence shows that a 
telephone call or alerting message from a chemical pathologist to the GP could have 
a powerful impact on whether an elevated cholesterol level was better investigated28. 
With GPs requesting over 90% of LDL-c levels in Australia, the opportunity for more 
innovative screening at the primary care level could be improved29, 30.  
The combination of greater reductions to target LDL-c levels and better use of 
specialist services could facilitate improvements in FH recognition and care. The 
shared care approach with GP management for lower to intermediate risk patients 
and specialist support for higher risk and more complex cases should be a logical 
development in care strategy. 
4. Use of health checks 
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FH is ideally suited to use of periodic health checks and subsequent care plan 
management as part of a strategic approach to manage this chronic disease in 
general practice. Much emphasis with FH to date has focussed on ‘top-down’ 
approaches with identification and management primarily in tertiary hospital clinics 
and specialist care. In the early, asymptomatic phase of FH, early diagnosis and 
appropriate diet, lifestyle and drug interventions can be provided at the primary care 
level. Easy access to primary care services and regular follow-up checks at local 
practices can be provided. In Australia, care plans and 45-49 year-old health 
checks58 developed by GPs and PNs, can be supported by other health 
professionals including dieticians, exercise physiologists and clinical psychologists 
while cardiologists, lipid specialists, endocrinologists and paediatricians can also 
contribute as required.  
Many care plans have traditionally been viewed as mainly targeting the degenerative 
processes associated with ageing, diabetes, ischemic heart disease and strokes. FH 
can legitimately be added as a chronic lifelong condition that is well suited to a 
planned approach and management in primary care. Specialist help should always 
be available for more complex and difficult to manage patients and children. 
In the UK, the 40 – 74 year-old age group health checks58, 59 for patients with no 
recorded chronic health condition could be utilised to assess for FH risk. Patients 
with total cholesterol levels above 7.5mmol/l, should be targeted by GPs to 
undertake further investigations34, 60. 
5. Improve public awareness of FH 
Improving public awareness of the possibility of FH, especially in the community 
setting, needs to be addressed3, 50. Many families may be aware of premature CVD 
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deaths in their own households but the significance of these past events and the 
potential future risk to their own health is often not fully grasped. Young off-spring of 
affected patients are likely to feel entirely healthy and lacking in symptoms and see 
no reason to commence life-long treatment for a condition they perceive as posing 
no immediate or potential threat. It may take on some relevance when a friend or 
colleague develops a life-threatening heart attack at a young age and their own 
potential risk is suddenly brought into sharper focus22. High risk patients with 
potential FH or known FH patients who refuse or are non-compliant with best 
practice medications and lifestyle modifications, should be offered an ‘open door’ 
approach to be seen early if they change their mind re future treatments. 
6. Improve health professional awareness of FH 
Despite increasing knowledge about the prevalence and risks of FH, many health 
professionals do not make a connection between FH and the patient’s presenting 
condition3, 6, 50. A better appreciation of the underlying genetic nature of the 
disease10, 13, 61 and the fact that it will not be solely responsive to dietary and lifestyle 
intervention is needed.  
The current best management approach is through use of high intensity statins from 
a young age1, 9, 11, 12, 14, 26, 62. The lifetime increased accumulation of LDL-c means 
that the relative risk from FH makes the use of absolute CVD risk calculators63 
inappropriate in patients with FH and they should not be used1, 9, 11, 14, 26. Compliance 
with lifetime statin therapy may be a significant problem especially if family 
perceptions of such treatment is an issue12. GPs can play a major role in this area. 
7. Improve support in primary care for cascade screening of close relatives 
of index cases 
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Cascade screening of close family relatives of known index cases is recognised as 
the most efficient and cost-effective approach for identifying new FH patients3, 9, 64-66. 
The evidence to support cascade testing of relatives is based on specialist centre 
approaches rather than screening from primary care3. The UK National Health 
Service (NHS) has recognised the difficulties posed by a lack of suitable 
infrastructure in primary care to undertake systematic cascade screening, and 
recommend that it should be undertaken through specialist centres instead17, 34. 
Evidence from the Netherlands showed the success of using genetic field workers to 
target close relatives of new index cases in a systematic fashion27, 67. The Dutch FH 
program which sought to find all FH patients, was centrally controlled and involved 
all specialists in cardiovascular care as well as all GPs, and had extensive media 
and scientific journal exposure to increase awareness at the general population and 
health professional levels27. 
Experience from the Danish General Population study on FH14 suggests that 
development of national models of care, and health policy integrating care between 
GPs and specialists, would achieve the best outcomes for individuals and families 
with FH. 
Density of population in close geographic proximity can help the cascade screening 
of relatives, with families in more remote locations and migrant families at a much 
greater risk of having a less effective service22, 68. 
Where does primary care screening for FH fit into Models of Care? 
The role of primary care in the detection and care of patients with FH is evolving but 
no consensus exists on the optimum screening strategy, on how best to integrate 
primary and specialist level care32, on genetic versus phenotypic testing3, 34, 69, on 
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childhood screening70, on sustainable methods of cascade testing close relatives of 
index cases71 and on recording family history72, 73. Table 2 provides suggested 
strategies for measuring cholesterol and genetic testing by age in a primary care 
practice. Low levels of public and health professional awareness of the disorder is 
central to this uncertainty as is poor compliance once a diagnosis is made9, 50. 
The traditional model of care for FH is based on the chronic care model3, 32 and aims 
to deliver the right treatment, for the right patient, at the right time, by the right team 
across the continuum of care. Of necessity, this will involve a major contribution from 
primary care but patients with the condition are not being recognised during routine 
clinical encounters1, 9, 14. The current infrastructure in primary care makes cascade 
screening very challenging3, 22. Research in UK estimated an upper limit of 40% 
success rate might be possible and that involved specialist centre supports34. 
Attempts at cascade testing in primary care have been limited but the option is being 
canvassed47. Tertiary hospital models of service delivery are unlikely to be 
sustainable in primary care. Targeting high risk individuals with family history of 
premature CVD would be useful9, 32, 33, 36. 
Unanswered questions on primary care detection of FH 
From this review, we propose new lines for research based on a framework 
proposed by Gidding et al in an American Heart Association statement on FH1. 
Table 3 summarises topics that cover new diagnostic applications, population 
science, clinical research, patient-centric questions and models of care. Public 
consultation regarding all research aspects, particularly detection methods such as 
universal screening is recommended74. 
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The challenge of identifying new index cases of FH in the community setting75 
requires much more than opportunistic case finding during routine GP consultations, 
followed by cascade testing of close family relatives76. Universal screening 
approaches together with reverse cascade testing in the child-parent setting has 
shown good potential,40, 41, 77 but should be seen as part of a multi-faceted approach 
across community and hospital clinic settings that is integrated into routine clinical 
care75.  
The potential of FH Registries78-81 and improved coding for FH needs to be linked to 
screening approaches and establishment and harmonisation of the clinical 
diagnosis1, 26, 77. Primary care has a key role to play but lacks the infrastructure and 
supports offered by hospital lipid clinics. Such support will be critical if a sustainable 
primary care based model of care is to be established1. 
Conclusion  
Primary care can improve the detection and care of FH patients through an efficient, 
cost-effective and sustainable approach acceptable to patients, families and health 
professionals1, 3, 9. This approach should straddle the entire continuum of care3, 9, 32, 
82 – general practice, lipid specialists, cardiology, paediatrics, endocrinology, 
pathology, genetics and allied health. FH is best diagnosed in childhood or early 
adolescence1, 9, 12, 14 followed by cascade testing of family members with 50% 
detection rates expected among first degree relatives1, 26, 64, 65. This allows for timely 
institution of lifelong medication and lifestyle changes to prevent the early 
development of atherosclerosis3, 9, 12,. A shared care model involving primary care for 
low risk and specialist support for high risk and difficult to manage patients, would be 
ideal. 
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Increased awareness of potential FH among the public and among health 
professionals is required1, 50. GPs and PNs should grasp the implications of a 
diagnosis of FH1, 3, 9, 12, 50, and the need for follow-up checks to monitor compliance 
and treatment targets1, 9, 12, 14, 50. Patients need re-enforcement that achieving LDL-c 
targets will reduce their cumulative lifetime risk for premature CAD12, 50. Chronic 
disease care plans are a cost-effective way for general practice to manage such 
care22, 58. 
At community level, families with history of early heart disease should be especially 
targeted1, 3, 12. Primary care with its ease of access and frequent patient contact can 
help in this regard18, 19 Patients and families with FH need reminding that they are at 
significantly greater risk for CVD compared to those without50. Better education for 
the newly diagnosed young and regular follow-up to ensure compliance will be 
necessary12, 82. Wald et al’s40 targeting of 92 general practices to universally screen 
over 10,000 toddlers aged 1-2 years at routine immunisation attendances with 84% 
parent approval offers hope for the future. Childhood detection allowed reverse 
cascade screening of parents (50% pickup) and saved lives40. 
A combination of opportunistic case-finding, systematic and universal screening of 
general practice databases33, 36, 47 increased public and health professional 
awareness of the disease1, 3, 9, 14, and better education and treatment knowledge 
among primary care teams1, 50, especially the need for lifetime care with specialist 
support, is required. 
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Table 1. Screening criteria for FH and role and opportunities for primary care 
Screening Criteria  
(1) The screening 
programme should 
respond to a 
recognised need 
 Over 85% of patients with FH have not been 
identified2.   
 Without treatment CHD develops1, 3, 9.  
(2) The objective of 
screening should be 
defined at the outset. 
 Identification of patients at  very high risk of 
premature CHD1, 3, 9.  
 High intensity lipid lowering treatment can lead to 
48% reduction in CHD mortality1, 3, 9.  
(3) There should be a 
defined target 
population. 
Less consensus, but is based on an interplay of an 
individual’s cholesterol levels and family history of 
premature coronary heart disease, familial 
hypercholesterolemia and/or raised cholesterol eg: 
 Cholesterol levels > 9.3 mmol/l indicated FH in 28% 
of patients60  
 Cholesterol levels > 7.5mmol/l should trigger further 
assessment of FH2, 35   
 Personal or family history of premature CHD17  
 Diagnostic criteria such as the DLCN42, MEDPED43 
and S-B criteria44 
 
(4) There should be 
scientific evidence of 
screening programme 
effectiveness.   
Case series and interventional studies49 show 
improvement in the number of new cases identified with 
possible or definite FH. 
 
(5) The programme 
should integrate 
education, testing, 
clinical services and 
programme 
management. 
Several countries integrate preventative programmes 
and care pathways from primary  to specialist care 1, 3, 9 
(see section “Potential approaches to screening in 
primary care”). 
(6) There should be 
quality assurance, 
with mechanisms to 
minimise potential 
risks of screening.   
 Lipid tests are available to internationally 
recognised standard (currently ISO 17043 in UK 
and NPAAC83 in Australia) 
 Family history recording of a three generation 
pedigree is standard in specialist care but the 
requirement for primary care is unclear. This could 
be a detailed family history collection or a less 
sensitive method of a few direct questions84 
 Genetic testing will require agreed standard of 
testing and interpretation prior to adoption.  
Currently the gold standard is NGS69, 85, 86 as a cost 
saving method87,88 but risks missing phenotypic 
FH3. 
(7) The programme 
should ensure 
informed choice, 
 Patients offered genetic testing within standard 
ethical framework including fully informed of the 
implications of testing 3, 89.   
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confidentiality and 
respect for autonomy.   
 Cholesterol testing is offered as part of routine 
clinical care - implications for testing and detection of 
FH may not be appreciated initially  45. 
 
(8) The programme 
should promote 
equality and access to 
screening to the entire 
target population. 
Identification of FH in primary care could involve 
opportunistic identification at review by GP or through 
programmes such as the UK national vascular check 
programme59 which has improved assessment in 
deprived communities90. 
(9) Programme 
evaluation should be 
planned from the 
outset 
From inception of an FH screening programme in 
primary care, key measures assessed should include: 
 process measures such as recruitment rate and 
specialist care attendance rate  
 outcome measures such as identification rates of  
FH and proportion of confirmed FH patients treated 
to target  
(10) The overall 
benefits of screening 
should outweigh the 
harm. 
 Reducing premature CHD is the prime target of FH 
screening1, 3, 9.   
 The false positive diagnostic rate44 is a potential 
harm but better use of algorithms  (FAMCAT36 and 
TARB-Ex33) may increase specificity  
 The psychological impact of a diagnosis is 
considered minimal but evidence for  short-term 
increase in anxiety is recognised 56, 57 
 
FH: Familial hypercholesterolaemia 
CHD: Coronary Heart Disease 
DLCN: Dutch Lipid Clinic Network  
MEDPED: Make Early Diagnosis to Prevent Early Deaths 
S-B: Simon-Broome 
NPAAC: National Pathology Accreditation Advisory Council  
DNA: Deoxyribonucleic Acid 
NGS: Next Generation Sequencing  
FAMCAT: Familial Hypercholesterolaemia Case Ascertainment Tool  
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Table 2. Tentative recommendations for screening by age for FH in primary 
care 
Age (years) Cholesterol 
Testing 
Genetic 
Testing 
CASCADE 
testing if 
patient is 
index case 
CASCADE 
testing if first 
degree 
relative 
positive 
0-2  No, unless 
both parents 
have high 
cholesterol 
Both parents 
gene positive 
Test parents 
and siblings 
Both parents 
positive 
(elevated 
cholesterol or 
gene positive) 
2-11 > 2 years with 
positive family 
history; 
otherwise 
between age 5 
and 11 by 
guidelines 
LDL-c > 190 
mg/dL and 
positive family 
history 
Test parents 
and siblings 
Parent or 
sibling gene 
positive 
12-30 If not tested 
previously, 
optimally by 
age 21 years 
Meet S-B, 
DLCN, 
MEDPED or 
other criteria 
for phenotypic 
FH 
Test parents 
and siblings 
Parent or 
sibling gene 
positive 
30-60 Per adult 
guidelines 
Meet S-B, 
DLCN, 
MEDPED or 
other criteria 
for phenotypic 
FH 
Test all first 
degree 
relatives 
Parent, sibling, 
or child gene 
positive 
> 60 Per adult 
guidelines 
Meet S-B, 
DLCN, 
MEDPED or 
other criteria 
for phenotypic 
FH 
Test all first 
degree 
relatives 
Child or sibling 
gene positive 
 
FH: Familial hypercholesterolaemia 
LDL-c: Low Density Lipoprotein-cholesterol 
S-B: Simon-Broome 
MEDPED: Make Early Diagnosis to Prevent Early Deaths  
DLCN: Dutch Lipid Clinic Network  
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Table 3. Knowledge gaps and suggestions for future research on FH screening 
in primary care. 
Science: Analytical Methods 
 Assessment of role cholesterol gene scores in testing for FH  
 Development of point-of-care lipid testing - total and LDL-cholesterol 
and Lp(a)  
 Development of point-of-care DNA testing 
 Compare genomic strategies Sequence  vs Chip & Sequence 
Epidemiology 
 Identification of new gene founder populations 
 Genetic epidemiology of FH in diverse communities 
 Development and application of registries  
 Development and testing of universal screening protocols 
 Data linkage studies between primary care and specialist databases 
Clinical Research (diagnostics, risk prediction, intervention trials) 
 Risk communication of genetic variants 
 Role of risk prediction algorithms in screening for FH  
 Clinical trials of screening protocols and testing interventions  
 Enhancing cascade testing methods in the community 
 Perceptions and psychological sequelae of genetic testing 
 Development of new selective screening protocols 
 Enhancing the use of information technology in case detection 
Patient-centric 
 Health literacy and understanding of genomics and genetic testing 
 Education of public and patients on genomics and role in healthcare 
 Insurance implications of genetic testing 
 Public consultations regarding screening methods for FH 
 Advocacy for raising awareness about genomics and genetic testing 
Models of Care 
 Education of primary care health professionals in genomic medicine 
 Development and testing of primary care based models  
 Roles of Specialists, General Practitioners, Practice nurses and 
Pharmacists in detection and follow-up 
 Design of education, training and accreditation programs in genomic 
medicine 
 Incorporation of cascade testing for Lp(a) within a primary care model 
  
FH: Familial hypercholesterolaemia 
LDL: Low Density Lipoprotein 
Lp(a): Lipoprotein(a) 
DNA: Deoxyribonucleic Acid 
 
